Literature DB >> 25542813

Galectin-1 in injured rat spinal cord: implications for macrophage phagocytosis and neural repair.

Andrew D Gaudet1, David R Sweet2, Nicole K Polinski2, Zhen Guan2, Phillip G Popovich3.   

Abstract

Galectin (Gal)-1 is a small carbohydrate-binding protein and immune modulatory cytokine that is synthesized locally at the site of peripheral nerve injury. In this environment, Gal1 can promote regeneration of injured peripheral axons, in part by modifying the function of macrophages recruited to the site of injury. Unlike in injured peripheral nerves, macrophages do not promote axon regeneration in the injured central nervous system (CNS), perhaps because Gal1 levels are not regulated appropriately. Because the dynamics and cellular localization of endogenous Gal1 have not been rigorously characterized after CNS injury, we examined the spatio-temporal distribution of Gal1 in rat spinal cords subjected to a standardized contusion injury. Whereas Gal1 was not expressed in uninjured spinal cord, it was significantly upregulated after SCI, especially within the lesion core. Gal1 was expressed in ~40% of lesion-localized macrophages at 3-28 days post-injury (dpi), and in ~45% of astrocytes in the lesion border at 7-28 dpi. Most lesion-localized Gal1+ macrophages did not express the phagocytosis marker ED1, and Gal1+ cells contained less phagocytosed lipids. These data suggest that time- and location-dependent regulation of Gal1 by macrophages (and astrocytes) could be important for modulating phagocytosis, inflammation/gliosis, and axon growth after SCI.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extracellular matrix; Glial scar; Inflammation; Neuroinflammation; Phagocytosis; Spinal cord injury

Mesh:

Substances:

Year:  2014        PMID: 25542813      PMCID: PMC4324335          DOI: 10.1016/j.mcn.2014.12.006

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  50 in total

Review 1.  Alternative activation of macrophages: an immunologic functional perspective.

Authors:  Fernando O Martinez; Laura Helming; Siamon Gordon
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

2.  Transplantation of galectin-1-expressing human neural stem cells into the injured spinal cord of adult common marmosets.

Authors:  Junichi Yamane; Masaya Nakamura; Akio Iwanami; Masanori Sakaguchi; Hiroyuki Katoh; Masayuki Yamada; Suketaka Momoshima; Sachiyo Miyao; Ken Ishii; Norikazu Tamaoki; Tatsuji Nomura; Hirotaka James Okano; Yonehiro Kanemura; Yoshiaki Toyama; Hideyuki Okano
Journal:  J Neurosci Res       Date:  2010-05-15       Impact factor: 4.164

3.  Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord.

Authors:  Kristina A Kigerl; John C Gensel; Daniel P Ankeny; Jessica K Alexander; Dustin J Donnelly; Phillip G Popovich
Journal:  J Neurosci       Date:  2009-10-28       Impact factor: 6.167

4.  Activation of RAW264.7 macrophages by oxidized galectin-1.

Authors:  Yu Echigo; Hayato Sugiki; Yuya Koizumi; Shinya Hikitsuchi; Hiroko Inoue
Journal:  Immunol Lett       Date:  2010-04-02       Impact factor: 3.685

5.  Expression of galectin-1 in immune cells and glial cells after spinal cord injury.

Authors:  Dai Kurihara; Masaki Ueno; Tatsuhide Tanaka; Toshihide Yamashita
Journal:  Neurosci Res       Date:  2009-11-24       Impact factor: 3.304

6.  A role for galectin-1 in the immune response to peripheral nerve injury.

Authors:  Andrew D Gaudet; Margaret Leung; Françoise Poirier; Toshihiko Kadoya; Hidenori Horie; Matt S Ramer
Journal:  Exp Neurol       Date:  2009-09-17       Impact factor: 5.330

7.  Temporal and spatial dynamics of peroxynitrite-induced oxidative damage after spinal cord contusion injury.

Authors:  Kimberly M Carrico; Radhika Vaishnav; Edward D Hall
Journal:  J Neurotrauma       Date:  2009-08       Impact factor: 5.269

Review 8.  Exploring the full spectrum of macrophage activation.

Authors:  David M Mosser; Justin P Edwards
Journal:  Nat Rev Immunol       Date:  2008-12       Impact factor: 53.106

Review 9.  Interactions between Schwann cells and macrophages in injury and inherited demyelinating disease.

Authors:  Rudolf Martini; Stefan Fischer; Rubèn López-Vales; Samuel David
Journal:  Glia       Date:  2008-11-01       Impact factor: 8.073

10.  Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis.

Authors:  John T Pesce; Thirumalai R Ramalingam; Margaret M Mentink-Kane; Mark S Wilson; Karim C El Kasmi; Amber M Smith; Robert W Thompson; Allen W Cheever; Peter J Murray; Thomas A Wynn
Journal:  PLoS Pathog       Date:  2009-04-10       Impact factor: 6.823

View more
  11 in total

Review 1.  Glial Cells Shape Pathology and Repair After Spinal Cord Injury.

Authors:  Andrew D Gaudet; Laura K Fonken
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

Review 2.  Tissue Engineering Approaches to Modulate the Inflammatory Milieu following Spinal Cord Injury.

Authors:  Courtney M Dumont; Daniel J Margul; Lonnie D Shea
Journal:  Cells Tissues Organs       Date:  2016-10-05       Impact factor: 2.481

3.  Neuroprotective Effect of Exogenous Galectin-1 in Status Epilepticus.

Authors:  Amanda Larissa Dias Pacheco; Igor Santana de Melo; Maisa de Araujo Costa; Mariah Morais Celestino Amaral; Nívea Karla de Gusmão Taveiros Silva; Yngrid Mickaelli Oliveira Santos; Daniel Leite Góes Gitaí; Marcelo Duzzioni; Alexandre Urban Borbely; Robinson Sabino Silva; Ana Luiza Ferreira Donatti; Luisa Mestriner; Carlos Alessandro Fuzo; Richard D Cummings; Norberto Garcia-Cairasco; Marcelo Dias-Baruffi; Olagide Wagner de Castro
Journal:  Mol Neurobiol       Date:  2022-09-29       Impact factor: 5.682

Review 4.  Neuroinflammation and galectins: a key relationship in neurodegenerative diseases.

Authors:  Eleazar Ramírez Hernández; Beatriz Alanis Olvera; Daniela Carmona González; Oscar Guerrero Marín; Denisse Pantoja Mercado; Lucero Valencia Gil; Luis F Hernández-Zimbrón; José Luis Sánchez Salgado; I Daniel Limón; Edgar Zenteno
Journal:  Glycoconj J       Date:  2022-06-02       Impact factor: 3.009

5.  miR-155 Deletion in Mice Overcomes Neuron-Intrinsic and Neuron-Extrinsic Barriers to Spinal Cord Repair.

Authors:  Andrew D Gaudet; Shweta Mandrekar-Colucci; Jodie C E Hall; David R Sweet; Philipp J Schmitt; Xinyang Xu; Zhen Guan; Xiaokui Mo; Mireia Guerau-de-Arellano; Phillip G Popovich
Journal:  J Neurosci       Date:  2016-08-10       Impact factor: 6.167

6.  High-throughput proteomics reveal alarmins as amplifiers of tissue pathology and inflammation after spinal cord injury.

Authors:  Athanasios Didangelos; Michele Puglia; Michaela Iberl; Candela Sanchez-Bellot; Bernd Roschitzki; Elizabeth J Bradbury
Journal:  Sci Rep       Date:  2016-02-22       Impact factor: 4.379

7.  Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke.

Authors:  Han Dong; Zhi-Hao Wang; Na Zhang; Si-Da Liu; Jian-Jun Zhao; Song-Yan Liu
Journal:  Oncotarget       Date:  2017-05-25

8.  Galectin-1 expression imprints a neurovascular phenotype in proliferative retinopathies and delineates responses to anti-VEGF.

Authors:  Magali E Ridano; Paula V Subirada; María C Paz; Valeria E Lorenc; Juan C Stupirski; Ana L Gramajo; José D Luna; Diego O Croci; Gabriel A Rabinovich; María C Sánchez
Journal:  Oncotarget       Date:  2017-05-16

9.  Galectin-1 enhances TNFα-induced inflammatory responses in Sertoli cells through activation of MAPK signalling.

Authors:  Tao Lei; Sven Moos; Jörg Klug; Ferial Aslani; Sudhanshu Bhushan; Eva Wahle; Suada Fröhlich; Andreas Meinhardt; Monika Fijak
Journal:  Sci Rep       Date:  2018-02-27       Impact factor: 4.379

10.  Animal Galectins and Plant Lectins as Tools for Studies in Neurosciences.

Authors:  João Ronielly Campêlo Araújo; Cauê Barbosa Coelho; Adriana Rolim Campos; Renato de Azevedo Moreira; Ana Cristina de Oliveira Monteiro-Moreira
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.